From Information to Innovation
The companies of the IGES Group support healthcare systems and healthcare technologies. We have been providing research and consulting for more than 40 years: analyses, expert opinions, studies, concepts and strategies in Europe.
6,000
Projects
200
Employees
13
Companies
8
Countries
Business division
Business division
- Germany
- France
- Italy
- Netherlands
- Spain
- Sweden
- Switzerland
- UK
New branch in Spain: IGES Pharma now with locations in eight European countries
The IGES Group has opened another location in Europe. It now also has a branch in Spain and offers consulting services for the Spanish and Portuguese pharmaceutical market. » Details
New branch in Spain: IGES Pharma now with locations in eight European countries
The IGES Group has opened another location in Europe. It now also has a branch in Spain and offers consulting services for the Spanish and Portuguese pharmaceutical market. » Details
IGES Group continues internationalisation and joins the athagoras Group
The IGES Group joined the athagoras Group in March 2025 in order to drive forward internationalisation and expertise in the healthcare sector in a consistent and future-oriented manner. » Details
IGES panel at Bio Europe Spring: independent commercialisation is becoming increasingly important for biotech start-ups
This is because more and more biotech companies are deciding not to out-license the drug they have developed, but to bring it onto the market themselves. » Details
Independent marketing instead of out-licensing? Panel discussion at Bio Europe Spring
This is because more and more biotech companies are deciding not to out-license the drug they have developed, but to bring it onto the market themselves. » Details
Update: new guide provides information on the European pricing and reimbursement system for innovative pharmaceutical products
Due to high demand, IGES experts have reissued the successful guide on the European reimbursement and pricing systems for pharmaceutical products. It also provides updated information on the harmonisation of the benefit assessment of new therapies at EU level. » Details
IGES
